Trump family AI project WorldClaw forms strategic partnership with VergeX AI to jointly build Agentic Trading infrastructure
According to ChainCatcher, the Trump family AI infrastructure project WorldClaw and VergeX AI have announced a strategic partnership. The two sides will jointly advance the development of next-generation AI-native trading infrastructure and accelerate the construction of the emerging Agentic Trading (intelligent trading) market.
It is reported that VergeX AI will integrate WorldClaw’s AI access layer into its Harness-driven autonomous multi-agent trading infrastructure, aimed at enabling the deployment of more scalable, accessible, and cost-effective professional-grade AI trading systems. Currently, VergeX AI is building an autonomous multi-agent trading operating system for the AI-native financial era. Its core Harness architecture serves as a layer for agent collaboration and task coordination, supporting trading execution across multiple markets including cryptocurrency, US equities, forex, and commodities.
Additionally, both parties stated that this cooperation aims to lower the threshold for building professional-grade AI trading agents and jointly promote the development of next-generation autonomous financial system infrastructure. The market generally believes that, as AI agents evolve from auxiliary tools to autonomous market participants, autonomous agents, AI-native execution systems, and programmable financial infrastructure are becoming the next trillion-dollar sectors of focus in the industry.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
